Alpha 2.0
Login Register
» Authors » E Connick

E Connick

Explore the profile of E Connick including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 33
Citations 1017
Followers 0
Related Specialties
Infectious Diseases
Neurology
Endocrinology
Top 10 Co-Authors
M M Lederman
D R Kuritzkes
A Landay
J Spritzler
H Kessler
M St Clair
L Fox
L Kirsteins
A M Lawrence
H Wu
Published In
J Infect Dis
AIDS
AIDS Res Hum Retroviruses
Neuroendocrinology
Blood
Affiliations
Soon will be listed here.
Recent Articles
1.
Immune reconstitution in HIV-1-infected individuals treated with potent antiretroviral therapy
Connick E
J Investig Dermatol Symp Proc . 2002 Apr; 6(3):212-8. PMID: 11924830
Potent combination antiretroviral therapy that was introduced in the mid-1990s for treatment of HIV-1 infection has resulted in unprecedented decreases in HIV-1 replication and increases in CD4+ T cell counts...
2.
Relationship between human immunodeficiency virus type 1 (HIV-1)-specific memory cytotoxic T lymphocytes and virus load after recent HIV-1 seroconversion
Connick E, Schlichtemeier R, Purner M, Schneider K, Anderson D, Mawhinney S, et al.
J Infect Dis . 2001 Dec; 184(11):1465-9. PMID: 11709791
Human immunodeficiency virus type 1 (HIV-1)-specific memory, or precursor, cytotoxic T lymphocytes (CTL) in 14 subjects who had recently experienced seroconversion were evaluated with respect to virus set point, defined...
3.
Multiple CD4+ cell kinetic patterns and their relationships with baseline factors and virological responses in HIV type 1 patients receiving highly active antiretroviral therapy
Wu H, Connick E, Kuritzkes D, Landay A, Spritzler J, Zhang B, et al.
AIDS Res Hum Retroviruses . 2001 Sep; 17(13):1231-40. PMID: 11559422
This exploratory analyses characterizes patterns of lymphocyte recovery in HIV-1-infected patients treated with highly active antiretroviral therapy (HAART) and investigates their relationship with baseline indices and virologic responses. We modeled...
4.
A potential role for interleukin-7 in T-cell homeostasis
Fry T, Connick E, Falloon J, Lederman M, Liewehr D, Spritzler J, et al.
Blood . 2001 May; 97(10):2983-90. PMID: 11342421
Interleukin (IL)-7 is known to up-regulate thymopoietic pathways of T-cell regeneration. Recent work also has shown it to potently enhance thymic-independent peripheral expansion and to restore immunocompetence in athymic T-cell-depleted...
5.
Ototoxicity associated with use of nucleoside analog reverse transcriptase inhibitors: a report of 3 possible cases and review of the literature
Simdon J, Watters D, Bartlett S, Connick E
Clin Infect Dis . 2001 May; 32(11):1623-7. PMID: 11340535
Although a variety of adverse effects have been attributed to treatment with nucleoside analog reverse transcriptase inhibitors (NRTIs) for human immunodeficiency virus type 1 (HIV-1) infection, only 5 cases of...
6.
Productive infection of T cells in lymphoid tissues during primary and early human immunodeficiency virus infection
Schacker T, Little S, Connick E, GEBHARD K, Zhang Z, Krieger J, et al.
J Infect Dis . 2001 Feb; 183(4):555-62. PMID: 11170980
Current models suggest that during human immunodeficiency virus type 1 (HIV-1) transmission virions are selected that use the CCR5 chemokine receptor on macrophages and/or dendritic cells. A gradual evolution to...
7.
Reduced susceptibility of human immunodeficiency virus type 1 (HIV-1) from patients with primary HIV infection to nonnucleoside reverse transcriptase inhibitors is associated with variation at novel amino acid sites
Brown A, Precious H, Whitcomb J, Wong J, Quigg M, Huang W, et al.
J Virol . 2000 Oct; 74(22):10269-73. PMID: 11044070
Recently, significant numbers of individuals with primary human immunodeficiency virus (HIV) infection have been found to harbor viral strains with reduced susceptibility to antiretroviral drugs. In one study, HIV from...
8.
Phase 1 trial of a single dose of recombinant human interleukin-12 in human immunodeficiency virus-infected patients with 100-500 CD4 cells/microL
Jacobson M, Hardy D, Connick E, Watson J, DeBruin M
J Infect Dis . 2000 Sep; 182(4):1070-6. PMID: 10979901
A phase 1 dose-escalation trial of a single subcutaneous dose of recombinant human (rh) interleukin (IL)-12 was conducted in medically stable human immunodeficiency virus (HIV)-infected patients with 100-500/microL absolute CD4(+)...
9.
Shipment impairs lymphocyte proliferative responses to microbial antigens
Betensky R, Connick E, Devers J, Landay A, Nokta M, Plaeger S, et al.
Clin Diagn Lab Immunol . 2000 Sep; 7(5):759-63. PMID: 10973450
Lymphocyte proliferation assays (LPAs) are widely used to assess T-lymphocyte function of patients with human immunodeficiency virus infection and other primary and secondary immunodeficiency disorders. Since these assays require expertise...
10.
Prolonged survival and tissue trafficking following adoptive transfer of CD4zeta gene-modified autologous CD4(+) and CD8(+) T cells in human immunodeficiency virus-infected subjects
Mitsuyasu R, Anton P, Deeks S, Scadden D, Connick E, Downs M, et al.
Blood . 2000 Jul; 96(3):785-93. PMID: 10910888
We have genetically engineered CD4(+) and CD8(+) T cells with human immunodeficiency virus (HIV) specificity by inserting a gene, CD4zeta, containing the extracellular domain of human CD4 (which binds HIV...